Simultaneous Assay of CA 72-4, CA 19-9, CEA and CA 125 in Biological Samples Using Needle Three-Dimensional Stochastic Microsensors. 2023

Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
Laboratory of Electrochemistry and PATLAB, National Institute of Research for Electrochemistry and Condensed Matter, 202 Splaiul Independentei Str., 060021 Bucharest, Romania.

Two-needle 3D stochastic microsensors based on boron- and nitrogen-decorated gra-phenes, modified with N-(2-mercapto-1H-benzo[d]imidazole-5-yl), were designed and used for the molecular recognition and quantification of CA 72-4, CA 19-9, CEA and CA 125 biomarkers in biological samples such as whole blood, urine, saliva and tumoral tissue. The NBGr-2 sensor yielded lower limits of determination. For CEA, the LOD was 4.10 × 10-15 s-1 g-1 mL, while for CA72-4, the LOD was 4.00 × 10-11 s-1 U-1 mL. When the NBGr-1 sensor was employed, the best results were obtained for CA12-5 and CA19-9, with values of LODs of 8.37 × 10-14 s-1 U-1 mL and 2.09 × 10-13 s-1 U-1 mL, respectively. High sensitivities were obtained when both sensors were employed. Broad linear concentration ranges favored their determination from very low to higher concentrations in biological samples, ranging from 8.37 × 10-14 to 8.37 × 103 s-1 U-1 mL for CA12-5 when using the NBGr-1 sensor, and from 4.10 × 10-15 to 2.00 × 10-7 s-1 g-1 mL for CEA when using the NBGr-2 sensor. Student's t-test showed that there was no significant difference between the results obtained utilizing the two microsensors for the screening tests, at a 99% confidence level, with the results obtained being lower than the tabulated values.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens
D018395 CA-19-9 Antigen Sialylated Lewis(a) blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors. 5-Acetylneuraminyl-2-3-Galactosyl-1-3-(Fucopyranosyl-1-4)-N-Acetylglucosamine,Antigen CA-19-9,Gastrointestinal Cancer Antigen,Sialyl Le(a),Sialyl Lewis A,Sialyl Lewis A Antigen,Sialyl Lewis(a) Tetrasaccharide,CA 19-9 Antigen,CA 19.9 Antigen,NAG-1,3-F-1,4-GN,Neu5Ac-2-3-Gal-1-3-(Fuc-1-4)-GlcNAc,alpha-Neu5Ac-(2-3)-beta-D-Gal-(1-3)-(alpha-L-Fuc-(1-4))-beta-D-GlcNAc,A, Sialyl Lewis,Antigen CA 19 9,Antigen, CA 19-9,Antigen, CA 19.9,Antigen, CA-19-9,CA 19 9 Antigen,CA-19-9, Antigen,Cancer Antigen, Gastrointestinal,Lewis A, Sialyl

Related Publications

Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 1988, The International journal of biological markers,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
August 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 2002, Anticancer research,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 2004, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 2022, Arquivos de gastroenterologia,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
July 1999, Oncology,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
October 2008, Advances in therapy,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 1995, The International journal of biological markers,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 1999, The International journal of biological markers,
Alexandru-Adrian Bratei, and Raluca-Ioana Stefan-van Staden, and Ruxandra-Maria Ilie-Mihai, and Damaris-Cristina Gheorghe
January 1997, Anticancer research,
Copied contents to your clipboard!